Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 5c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Join SI Premium – FREE
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($0.52), $0.05 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $77.8 million versus the consensus estimate of $75.2 million.
GUIDANCE:
Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $310-320 million, versus the consensus of $312.7 million.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia Extends Decline To 7.3%, Biggest Drop Since April 2025
- Advanced Micro Devices falls on regulatory concerns, broad selloff
- Nasdaq 100 Extends Decline To 5.1%, S&P 500 Down 2.8%
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
